Mitsubishi Tanabe Pharma to Present ND0612 Data at 2024 Parkinson's Congress
- Mitsubishi Tanabe Pharma America will showcase seven presentations on ND0612 at the 2024 International Congress of Parkinson's Disease and Movement Disorders.
- The data will include findings from the pivotal Phase 3 BouNDless trial, focusing on patient-reported outcomes and one-year results from the open-label extension phase.
- This initiative underscores MTPA's commitment to advancing research and understanding of Parkinson's disease, which affects nearly one million people in the U.S.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced that it will present seven studies on investigational ND0612, a treatment for Parkinson's disease, at the 2024 International Congress of Parkinson's Disease and Movement Disorders in Philadelphia from September 27 to October 1. The presentations will include data from the pivotal Phase 3 BouNDless trial, focusing on the treatment's effectiveness in managing motor fluctuations in patients. Key findings will cover patient-reported outcomes related to quality of life and daily living experiences. Additionally, the company will discuss one-year outcomes from the ongoing open-label extension phase of the trial, which aims to provide further insights into the long-term effects of ND0612. MTPA is committed to advancing research in Parkinson's disease, a condition affecting nearly one million individuals in the U.S., and will also host an educational discussion on the disease during the symposium.